In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Insmed's current price exceeds the PERT fair value by 19%, with high-confidence valuations signaling possible overvaluation versus intrinsic worth, particularly as DCF indicates significant negative mid-values. Strong liquidity and growth contrast with zero profitability and efficiency scores, reflecting financial health risks. The Monte Carlo analysis shows minimal downside risk below current price, highlighting price resilience despite valuation concerns.